Generated

Novo Nordisk faces sales disappointment with Wegovy pill while Eli Lilly surpasses analyst expectations for injectable franchise.

Novo Nordisk reported a research disappointment and a miss on Wegovy pill sales, while Eli Lilly's injectable franchise continued to exceed analyst expectations. The Danish drugmaker Novo Nordisk is attempting to regain market share from Eli Lilly, which has seen its stock value soar past the trillion-dollar mark. Novo Nordisk reported that the Wegovy pill had sales of approximately $494 million in the second quarter, falling short of the 3.6 billion kroner expected by analysts. Meanwhile, Eli Lilly's Foundayo pill sales also fell short of expectations, but investors remained positive on the company's overall performance. Both Novo Nordisk and and Eli Lilly raised their revenue estimates for the year. Novo Nordisk projected adjusted sales at constant currency exchange rates will either stay flat or drop by as much as 6% this year, improving from a previous estimate of a 4% to 12% decline.

Sources